Thursday, May 26, 2011

SARS Envelope Antibody


Catalog# :3531

A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2 (4).

Additional Names : SARS Envelope (NT), SARS, SARS E, SARS Env

Source :SARS envelope antibody was raised against a synthetic peptide corresponding to amino acids at the amino-terminus of the SARS envelope protein.
Purification : Affinity chromatography purified via peptide column
Clonality and Clone : This is a polyclonal antibody.
Host : SARS Envelope antibody was raised in rabbit.
Please use anti-rabbit secondary antibodies.
Immunogen : Human SARS Envelope (N-Terminus) Peptide (Cat. No. 3531P)
Application : SARS envelope antibody can be used for the detection of SARS envelope protein in ELISA. It will detect 10 ng of free peptide at 1 µg/ml.Other applications are pending.
Tested Application(s) : E
Buffer : Antibody is supplied in PBS containing 0.02% sodium azide.
Blocking Peptide :Cat. No. 3531P - SARS Envelope Peptide
Long-Term Storage : SARS Envelope antibody can be stored at 4ºC, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Species Reactivity : V
GI Number : 30173401
Accession Number : P59637
Short Description : (NT) SARS virus envelope protein
References
1. Marra MA, Jones SJ, Astell CR, et al. The Genome sequence of the SARS-associated corona virus. Science 2003;300:1399-404.
2. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300:1394-9.
3. Navas-Nartin SR and Weiss S. Coronavirus replication and pathogenesis: Implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development. J Neurovirol. 2004;10:75-85.
4. Arbely E, Khattari Z, Brotons G, et al. A highly unusual palindromic transmembrane helical hairpin formed by SARS coronavirus E protein. J Mol. Biol. 2004;3414:769-79.

1 comment:

antibody said...

Hi all,

Severe acute respiratory syndrome or SARS continues to be reported primarily among people who have travelled to affected areas. A small number of other people have become infected after being in close contact with or having cared for or lived with a SARS patient. Thanks a lot!